Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.
“Velaglucerase alfa ghu, the active ingredient in VPRIV, supplements or replaces beta- glucocerebrosidase, the enzyme that catalyses the hydrolysis of glucocerebroside to glucose and ceramide in the lysosome, reducing the amount of accumulated glucocerebroside and correcting the pathophysiology of Gaucher disease.”
“After the end of the infusion, velaglucerase alfa ghu serum concentrations fell rapidly in a monophasic or biphasic fashion with a mean t ½ ranging from 5 to 12 minutes for the 15, 30, 45 and 60 U/kg doses.”
Working under the parallel aged-care framework? Aged-care equivalent →